| Treatment of advanced prostate cancer MY Teo, DE Rathkopf, P Kantoff Annual review of medicine 70, 479-499, 2019 | 434 | 2019 |
| Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ... Journal of Clinical Oncology 36 (17), 1685, 2018 | 410 | 2018 |
| DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, ... Clinical cancer research 23 (14), 3610-3618, 2017 | 216 | 2017 |
| The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme RM Bambury, MY Teo, DG Power, A Yusuf, S Murray, JE Battley, C Drake, ... Journal of neuro-oncology 114, 149-154, 2013 | 193 | 2013 |
| The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme RM Bambury, MY Teo, DG Power, A Yusuf, S Murray, JE Battley, C Drake, ... Journal of neuro-oncology 114, 149-154, 2013 | 193 | 2013 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 149 | 2022 |
| Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy EJ Pietzak, EC Zabor, A Bagrodia, J Armenia, W Hu, A Zehir, S Funt, ... European urology 75 (2), 231-239, 2019 | 113 | 2019 |
| Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer D Liu, P Abbosh, D Keliher, B Reardon, D Miao, K Mouw, A Weiner-Taylor, ... Nature communications 8 (1), 2193, 2017 | 104 | 2017 |
| Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib SJ Cushen, DG Power, MY Teo, P MacEneaney, MM Maher, R McDermott, ... American journal of clinical oncology 40 (1), 47-52, 2017 | 101 | 2017 |
| Cancer susceptibility mutations in patients with urothelial malignancies MI Carlo, V Ravichandran, P Srinavasan, C Bandlamudi, Y Kemel, ... Journal of Clinical Oncology 38 (5), 406, 2020 | 64 | 2020 |
| PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among three commonly used and commercially available antibodies H Reis, R Serrette, J Posada, V Lu, Y Chen, A Gopalan, SW Fine, ... The American journal of surgical pathology 43 (7), 920, 2019 | 61 | 2019 |
| Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation? J Naidoo, MY Teo, S Deady, H Comber, P Calvert Journal of Thoracic Oncology 8 (9), 1215-1221, 2013 | 50 | 2013 |
| Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, ... Journal of Clinical Oncology 40 (12), 1312-1322, 2022 | 36 | 2022 |
| DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy Y Ged, JL Chaim, RG DiNatale, A Knezevic, RR Kotecha, MI Carlo, ... Journal for immunotherapy of cancer 8 (1), 2020 | 34 | 2020 |
| NUT Midline Carcinoma in a Young Woman MY Teo, P Crotty, M O'Sullivan, CA French, JM Walshe Journal of Clinical Oncology 29 (12), e336-e339, 2011 | 27 | 2011 |
| Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) P Grivas, Y Loriot, R Morales-Barrera, MY Teo, Y Zakharia, S Feyerabend, ... BMC cancer 21 (1), 1-13, 2021 | 26 | 2021 |
| Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy MY Teo, MSNM Sharial, F McDonnell, KC Conlon, PF Ridgway, ... Tumori Journal 99 (4), 516-522, 2013 | 25 | 2013 |
| Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial … MY Teo, JM Mota, KA Whiting, HA Li, SA Funt, CH Lee, DB Solit, ... European urology 78 (6), 907-915, 2020 | 21 | 2020 |
| Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): results from ATLAS, a phase II open-label trial. P Grivas, Y Loriot, S Feyerabend, R Morales-Barrera, MY Teo, ... Journal of Clinical Oncology 38 (6_suppl), 440-440, 2020 | 21 | 2020 |
| Nivolumab for the treatment of urothelial cancers MY Teo, JE Rosenberg Expert Review of Anticancer Therapy 18 (3), 215-221, 2018 | 21 | 2018 |
